MedTrace Logo

Radiation Therapy or Combination Chemotherapy in Treating Patients With Clinically or Radiologically Progressive Low-Grade Gliomas

NCT00276640 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 3417

Last updated 2018-04-20

No results posted yet for this study

Summary

RATIONALE: Radiation therapy uses high-energy x-rays to kill tumor cells. Drugs used in chemotherapy, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.

PURPOSE: This clinical trial is studying giving radiation therapy or combination chemotherapy to see how well it works in treating patients with clinically or radiologically progressive low-grade gliomas.

Conditions

  • Primary Central Nervous System Neoplasms

Interventions

DRUG

vincristine, carboplatin

vincristine: 1,5 mg/m² i.v., week 1,2,3,4,5,6,7,8,9,10,13,17,21 carboplatin: 550 mg/m² i.v., week 1,4,7,10,13,17,21

DRUG

vincristine, carboplatin, etoposide

vincristine: 1,5 mg/m² i.v., week 1,2,3,4,5,6,7,8,9,10,13,17,21 carboplatin: 550 mg/m² i.v., week 1,4,7,10,13,17,21 etoposide: 100 mg/m² i.v., week 1,4,7,10

RADIATION

radiation therapy

intracranial tumor site: 30 fractions, dose per fraction: 1.8 Gy, total dose: 54 Gy, duration 6 weeks spinal tumor site: 28 fractions, dose per fraction: 1.8 Gy, total dose: 50.4 Gy duration 5 1/2 weeks

Sponsors & Collaborators

  • Societe Internationale d'Oncologie Pediatrique

    lead OTHER

Principal Investigators

  • Astrid Gnekow · University Hospital Augsburg

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
1 Day
Max Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2004-04-01
Primary Completion
2015-12-31
Completion
2017-05-31

Countries

  • Austria
  • Belgium
  • Croatia
  • Denmark
  • France
  • Germany
  • Italy
  • Norway
  • Poland
  • Portugal
  • Switzerland
  • United Kingdom

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00276640 on ClinicalTrials.gov